- Tozadenant
-
- $15.00 / 1KG
-
2021-07-13
- CAS:870070-55-6
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- Tozadenant
-
- $15.00 / 1KG
-
2021-07-09
- CAS:870070-55-6
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| 4-Hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl-1-piperidinecarboxamide Basic information |
| 4-Hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl-1-piperidinecarboxamide Chemical Properties |
density | 1.374 | storage temp. | Store at -20°C | solubility | insoluble in EtOH; insoluble in H2O; ≥20.35 mg/mL in DMSO | form | Powder | pka | 14.95±0.20(Predicted) | color | White to off-white |
| 4-Hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl-1-piperidinecarboxamide Usage And Synthesis |
Description | Tozadenant is an adenosine A2A receptor antagonist (Kis = 11.5 and 6 nM for the human and rhesus monkey receptors, respectively). It increases the distance traveled and reduces contralateral asymmetry in the open field test in a rat model of Parkinson''s disease induced by 6-OHDA when administered at a dose of 30 mg/kg. Tozadenant (150 mg/kg) reverses locomotor deficits and restores novel object-stimulated locomotion in a marmoset model of MPTP-induced Parkinson''s disease. | Definition | ChEBI: Tozadenant is a member of benzothiazoles. | target | adenosine A2A receptor | references | hauser ra, olanow cw, kieburtz kd et al. tozadenant (syn115) in patients with parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. lancet neurol. 2014 aug;13(8):767-76. |
| 4-Hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl-1-piperidinecarboxamide Preparation Products And Raw materials |
|